The settlement benefits individuals and entities who indirectly purchased or paid for Suboxone and its AB-rated generic equivalents for themselves, their families, employees, plan participants, beneficiaries or insureds between Dec. 22, 201,1 and Aug. 21, 2023, in certain U.S. states.
